Patient and sample characteristics
Patient . | Gender . | Age . | Primary tumor . | . | . | . | Lymph node metastasis, tumor % . | . | . | . | ||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
. | . | . | Location . | Size (cm) . | Tumor % . | . | . | . | . | . | ||||||
. | . | . | . | . | >75 . | 50-75 . | >75 . | 50-75 . | 25-50 . | <10 . | ||||||
1 | M | 55 | Oral cavity | 3.0 | + | + | ||||||||||
2 | F | 62 | Oral cavity | 4.2 | + | + | ||||||||||
3 | M | 67 | Oropharynx | 7.3 | + | + | ||||||||||
4 | M | 52 | Oral cavity | 2.3 | + | + | ||||||||||
5* | F | 38 | Oral cavity | 4.0 | + | + | ||||||||||
7 | M | 51 | Oral cavity | 3.0 | + | + | ||||||||||
9* | M | 61 | Oropharynx | 3.5 | + | + | ||||||||||
10* | M | 42 | Oropharynx | 5.5 | + | + | ||||||||||
11* | F | 55 | Oral cavity | 6.0 | + | + | ||||||||||
13 | M | 82 | Oral cavity | 2.5 | + | + | ||||||||||
14 | F | 52 | Oropharynx | 7.0 | + | + | ||||||||||
17 | M | 61 | Oral cavity | 2.9 | + | + | ||||||||||
18* | M | 50 | Oral cavity | 3.0 | + | + | ||||||||||
19* | M | 66 | Oral cavity | 5.0 | + | + | ||||||||||
6† | M | 50 | Oral cavity | 4.0 | + | + | ||||||||||
8† | M | 58 | Oropharynx | 3.0 | + | + | ||||||||||
12† | F | 38 | Oropharynx | 4.0 | + | + | ||||||||||
15† | F | 63 | Oropharynx | 5.0 | + | + | ||||||||||
16† | M | 46 | Oral cavity | 5.2 | + | + |
Patient . | Gender . | Age . | Primary tumor . | . | . | . | Lymph node metastasis, tumor % . | . | . | . | ||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
. | . | . | Location . | Size (cm) . | Tumor % . | . | . | . | . | . | ||||||
. | . | . | . | . | >75 . | 50-75 . | >75 . | 50-75 . | 25-50 . | <10 . | ||||||
1 | M | 55 | Oral cavity | 3.0 | + | + | ||||||||||
2 | F | 62 | Oral cavity | 4.2 | + | + | ||||||||||
3 | M | 67 | Oropharynx | 7.3 | + | + | ||||||||||
4 | M | 52 | Oral cavity | 2.3 | + | + | ||||||||||
5* | F | 38 | Oral cavity | 4.0 | + | + | ||||||||||
7 | M | 51 | Oral cavity | 3.0 | + | + | ||||||||||
9* | M | 61 | Oropharynx | 3.5 | + | + | ||||||||||
10* | M | 42 | Oropharynx | 5.5 | + | + | ||||||||||
11* | F | 55 | Oral cavity | 6.0 | + | + | ||||||||||
13 | M | 82 | Oral cavity | 2.5 | + | + | ||||||||||
14 | F | 52 | Oropharynx | 7.0 | + | + | ||||||||||
17 | M | 61 | Oral cavity | 2.9 | + | + | ||||||||||
18* | M | 50 | Oral cavity | 3.0 | + | + | ||||||||||
19* | M | 66 | Oral cavity | 5.0 | + | + | ||||||||||
6† | M | 50 | Oral cavity | 4.0 | + | + | ||||||||||
8† | M | 58 | Oropharynx | 3.0 | + | + | ||||||||||
12† | F | 38 | Oropharynx | 4.0 | + | + | ||||||||||
15† | F | 63 | Oropharynx | 5.0 | + | + | ||||||||||
16† | M | 46 | Oral cavity | 5.2 | + | + |
NOTE: Primary tumors and lymph node metastasis samples are grouped according to their tumor percentage. Age is age at diagnosis; size is diameter of tumor in cm.
Patients of whom the analyzed metastasis sample contained <50% tumor cells.
Comprises five sample pairs for which the lymph node metastases samples contain <10% tumor cells and are referred to as low tumor percentage pairs.